Cathelicidin

Also known as: CAMP, LL-37 precursor, hCAP18

ImmunePRECLINICAL

Clinical Status

Preclinical — research on antimicrobial peptide therapeutics.

Mechanism of Action

A family of antimicrobial peptides stored in neutrophil granules. Upon activation, the precursor (hCAP18) is cleaved to release LL-37, which permeabilizes microbial membranes and recruits immune cells to infection sites.

Dosing Defaults

Dose

100-200 mcg

Frequency

1x daily

Administration

Subcutaneous injection or topical

Timing

Morning

Food

with or without

Duration

2-4 weeks

Dose range: 50-300 mcg daily

Morning dosing supports immune surveillance during active hours.

Side Effects

•Injection site reactions
•Local inflammation
•Possible allergic reaction
•Skin irritation (topical)

Contraindications & Warnings

•Not medical advice
•Research compound — limited human dosing data

Compare

Compare Cathelicidin with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your Cathelicidin dose.

Open Calculator

Related Immune Peptides

LL-37

PHASE 1

Immune

Antimicrobial peptide with broad-spectrum activity and wound healing properties.

KPV

PRECLINICAL

Immune

Anti-inflammatory peptide fragment. Does NOT cause immunosuppression.

Thymosin Alpha-1

PHASE 3

Immune

Thymic peptide for immune modulation. Approved in 35+ countries.

VIP

PHASE 2

Immune

Immunomodulatory peptide used in mold illness (CIRS) protocols.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.